Corporate calendar for Immutep Limited (IMMP): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $159M | |
| 2026-09-14 | $144M | |
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | ||
| 2026-09-14 | $0.01 | $139M |
| 2026-09-14 | $-0.00 | $3M |
Stock Splits
| Date | Ratio |
|---|---|
| 2026-09-28 | 1:20 |
| 2019-11-07 | 1:10 |
| 2019-07-15 | 1011:1000 |
| 2016-12-28 | 3:10 |
Price
| Price | $0.33 |
| Market Cap | $48M |
| Exchange | NASDAQ |
| Country | AU |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.50 |
Related companies: ACHV · ALLO · CABA · CADL · CAPR · EDIT · MREO
Explore sector: Healthcare · Biotechnology
More sections of IMMP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks